An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity
Kathryn L. Roche(Pennsylvania State University), Lillian W. Chiang(ALS Biopharma (United States)), Eain A. Murphy(Cleveland Clinic Lerner College of Medicine), William W. Reiley(Pennsylvania State University), Angela Wahl(University of North Carolina at Chapel Hill), J. Víctor García(University of North Carolina at Chapel Hill), Liudi Tang(ALS Biopharma (United States)), Ashley P. Barry(Duke University), Chandrav De(University of North Carolina at Chapel Hill), Micah A. Luftig(Duke University), James R. Tonra(ALS Biopharma (United States)), John L. Kulp(ALS Biopharma (United States)), Alison V. Welsh(ALS Biopharma (United States)), Thomas Shenk(Princeton University), Matthew J. Todd(ALS Biopharma (United States)), Stacy Remiszewski(ALS Biopharma (United States))
Cited by 27
Related Papers
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
|Nature Medicine|2021|367
HIV-1 Nef: at the crossroads
|Retrovirology|2008|209
Negative Regulation of JNK Signaling by the Tumor Suppressor CYLD
|Journal of Biological Chemistry|2004|149